ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,118.80
-0.50%
S&P ASX All Technology
3,503.30
-0.53%
Brent Oil
72.905
0.00%
US Dollar vs AUD
1.52486
0.00%
Bitcoin
69,683.00
0.29%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Marinus Pharmaceuticals Inc (MRNS) Share Price

Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals Inc (MRNS)

-3x Mrna
0.3279
0.025
(8.25%)
Closed 02 November 7:00AM
Delayed by 15 minutes
0.327
-0.0009
(-0.27%)
After Hours: 10:43AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
0.327
Bid
0.3234
Offer
0.327
Volume
2,260,785
0.3011 Day's Range 0.333
0.2603 52 Week Range 11.26
Market Cap
18.012M
Previous Close
0.3029
Open
0.302771
Last Trade
1000
@
0.327
(formt)
Last Trade Time
Financial Volume
US$ 732,266
VWAP
0.323899
Average Volume (3m)
2,408,991
Shares Outstanding
55,084,038
Dividend Yield
-
PE Ratio
-0.13
Earnings Per Share (EPS)
-2.57
Revenue
30.99M
Net Profit
-141.41M

About Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychi... Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.marinuspharma.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Marinus Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MRNS. The last closing price for Marinus Pharmaceuticals was US$0.30. Over the last year, Marinus Pharmaceuticals shares have traded in a share price range of US$ 0.2603 to US$ 11.26.

Marinus Pharmaceuticals currently has 55,084,038 shares in issue. The market capitalisation of Marinus Pharmaceuticals is US$16.68 million. Marinus Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.13.

Ask ADVFN Intelligence (AI)

MRNS Latest News

More News

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

8 hours ago
Edgar (US Regulatory)

Form 8-K - Current report

24 October 2024
Edgar (US Regulatory)

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

Trial did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency (p=0.09); results showed numerically higher response rates for ganaxolone than...

24 October 2024
Business Wire

Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today presented new data from the...

17 October 2024
Business Wire

Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens

New U.S. patent issued for ZTALMY® (ganaxolone) oral titration regimens cover the treatment of a range of epilepsy disorders, expiring September 2042 Marinus continues to grow its IP portfolio...

16 October 2024
Business Wire

Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting

Includes additional data from the Phase 3 RAISE trial in refractory status epilepticus (SE) and data from a retrospective claims-based analysis ​​on the management of SE Marinus Pharmaceuticals...

09 October 2024
Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement...

09 October 2024
Business Wire

Form 8-K - Current report

02 October 2024
Edgar (US Regulatory)

Form 8-K - Current report

20 September 2024
Edgar (US Regulatory)

Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day

Enrollment complete and on track to report topline data from the TrustTSC trial in tuberous sclerosis complex (TSC) in the first half of Q4 with NDA filing targeted for April 2025 TrustTSC...

20 September 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.02698.963678773740.30010.460.2603130687740.37970975CS
4-1.403-81.0982658961.731.960.260360382120.43232386CS
12-0.923-73.841.251.970.260324089910.60403305CS
26-1.073-76.64285714291.41.970.260316220010.84720588CS
52-6.583-95.26772793056.9111.260.260313724772.14541066CS
156-11.183-97.158992180711.5113.150.26037632374.34232206CS
260-0.853-72.28813559321.1820.040.260310755804.22925223CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VSTEVast Renewable Ltd
US$ 4.98
(149.00%)
68.46M
INVZWInnoviz Technologies Ltd
US$ 0.096
(96.71%)
22.71k
CDXCChromaDex Corporation
US$ 5.87
(68.19%)
37.58M
ATHAAthira Pharma Inc
US$ 0.606
(41.56%)
236.07M
TILEInterface Inc
US$ 23.24
(33.03%)
2.12M
EPIXESSA Pharma Inc
US$ 1.45
(-72.12%)
33.85M
ELABElevai Labs Inc
US$ 0.0288
(-51.19%)
201.61M
OSTOstin Technology Group Company Ltd
US$ 0.275
(-45.00%)
2.27M
LXRXLexicon Pharmaceuticals Inc
US$ 1.23
(-36.92%)
19.96M
VCIGVCI Global Ltd
US$ 0.0583
(-27.58%)
26.13M
ATHAAthira Pharma Inc
US$ 0.606
(41.56%)
236.07M
SQQQProShares UltraPro Short QQQ
US$ 7.44
(-2.11%)
214.96M
NVDANVIDIA Corporation
US$ 135.40
(1.99%)
206.38M
ELABElevai Labs Inc
US$ 0.0288
(-51.19%)
201.61M
INTCIntel Corporation
US$ 23.20
(7.81%)
171.4M

MRNS Discussion

View Posts
glenn1919 glenn1919 2 months ago
MNRS................................https://stockcharts.com/h-sc/ui?s=MNRS&p=W&b=5&g=0&id=p86431144783
👍️0
Money hunt Money hunt 7 months ago
1.27 Wall gong to get busted down Watch out shorties,
👍️0
Money hunt Money hunt 7 months ago
MRNS Has got bulls with balls dude
👍️0
Money hunt Money hunt 7 months ago
Watch out shorties We the Next PALI So you can all burn in hell where you belong
👍️0
ErnieBilco ErnieBilco 7 months ago
MRSN under $2
👍️0
Awl416 Awl416 7 months ago
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
👍️0
Monksdream Monksdream 7 months ago
MRNS under $10
👍️0
oldstocks oldstocks 9 months ago
Drug Companies making Epilepsy medication
MRNS $10.08
CERE $43.16
STOK $4.98
UCBJF $102.00
SNY $45.63
PFE $27.00
OTSUK $18.36
RespireRx Pharmaceuticals Ticker: RSPI
Is working on Revolutionary New Hope:
KRM-II-81 Drug-Resistant Epilepsy Patients

Don't take my word for it, look at the links that talk about it.

Link found on National Library of Medicine
The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders

https://pubmed.ncbi.nlm.nih.gov/35041859/

https://www.neurexplain.com/2024/01/17/revolutionary-krm-ii-81-a-new-hope-for-drug-resistant-epilepsy-patients/

National Institutes of Health
A clinical case of a 19-year-old male patient with pharmacoresistant seizures occurring following parieto-occipital tumor-resection at age 6 ...
KRM–II–81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10784158/
👍️0
matt51 matt51 1 year ago
Has Marinus enrolled the eighty-second patient for the phase 3 RSE trial?
👍️0
Cosa Cosa 2 years ago
Did you add more here? This recovered well from the bottom. I was putting all into ARDX and AUPH, didn't add any here.
👍️0
Cosa Cosa 2 years ago
Thanks, I will look.
👍️0
Ganz Ganz 2 years ago
Ha, our time is coming for MRNS Cosa, also check out MIRM
👍️0
Cosa Cosa 3 years ago
Good thing that's all you had lol! This is definitely not volatile enough to trade. And a good investment?...Time will tell.
👍️0
missile_systems missile_systems 3 years ago
Yeah Buddy…. Hoping for good news.
Just stumbled upon this on Friday afternoon.
Only had enough powder to grab a hundred shares.
Please don’t laugh too hard….lol.

Anyway, it’s weird that there haven’t been any posts on this board since before last Christmas!

Peace
mis
👍️0
Cosa Cosa 3 years ago
let's see what happens Monday...
👍️0
Cosa Cosa 3 years ago
Everything I have is Red, not a single green. lol!
👍️0
flsh56 flsh56 3 years ago
... don't look now, it's been six months since this happened, but mrns just decently broke through their 50dma
👍️0
Ganz Ganz 3 years ago
Cosa, you there ?
👍️0
Ganz Ganz 3 years ago
Cosa, good to see you on this board, MRNS - like AUPH - is primed to pop.
👍️0
whytestocks whytestocks 4 years ago
JUST IN: $MRNS 3 Biotech Stocks That Surged Last Week

Dozens of healthcare stocks grew by double-digit percentages last week, and shares of these three drugmakers rose further than nearly all of their peers. Clinical trial results, coronavirus vaccine progress, and a buyout were the major factors that turned these biotech stocks into big gainers la...

Read the whole news MRNS - 3 Biotech Stocks That Surged Last Week
👍️0
ClayTrader ClayTrader 4 years ago
* * $MRNS Video Chart 09-15-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
Cosa Cosa 4 years ago
Woohoo! Huge upswing
👍️0
whytestocks whytestocks 4 years ago
NEWS: $MRNS Top Penny Stocks To Buy, Sell Or Hold? Analysts Weigh In On These 4

4 Penny Stocks To Buy Right Now According To Analysts Whether you buy penny stocks because of analysts or simply use ratings in your overall strategy, it helps to get a full lay of the land. What I mean by this is that most retail traders will look at a few facets of certain companies. They...

Find out more MRNS - Top Penny Stocks To Buy, Sell Or Hold? Analysts Weigh In On These 4
👍️0
whytestocks whytestocks 4 years ago
Breaking News: $MRNS Nasdaq Rises Despite Nikola Hit; Marinus Soars

Many investors have been worried about the Nasdaq Composite (NASDAQINDEX: ^IXIC) lately. The index has taken a leadership role during 2020's huge rebound from the coronavirus bear market, but its steep decline in early September made some believe that the best of times for the Nasdaq were no...

Got this from MRNS - Nasdaq Rises Despite Nikola Hit; Marinus Soars
👍️0
UFO UFO 4 years ago
Just announced phase #3 results rocked. Stock is on the way to $10+.

UFO
👍️0
MKthe great MKthe great 4 years ago
??????
👍️0
UFO UFO 4 years ago
Go Marinus!

UFO
👍️0
whytestocks whytestocks 4 years ago
News: $MRNS Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results

Clinical trials remain on track, with Refractory Status Epilepticus (SE) trial expected to begin enrollment shortly CDKL5 deficiency disorder (CDD) pivotal topline results on track for Q3; Conference call to be scheduled to discuss CDD data release and business update Organiz...

Find out more MRNS - Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
👍️0
UFO UFO 4 years ago
On the move!

UFO
👍️0
ClayTrader ClayTrader 4 years ago
* * $MRNS Video Chart 05-29-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
UFO UFO 4 years ago
Go Marinus!

UFO
👍️0
agribusiness72 agribusiness72 4 years ago
minor pump from yahoo finance. will see how low it drops before buying in.
👍️0
UFO UFO 5 years ago
Looks like a move is on.

UFO
👍️0
ClayTrader ClayTrader 5 years ago
* * $MRNS Video Chart 03-16-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 years ago
* * $MRNS Video Chart 02-20-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 years ago
* * $MRNS Video Chart 02-18-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
nuclear profitz nuclear profitz 5 years ago
breaking out.
👍️0
Cosa Cosa 5 years ago
Good points. I'm sure they will find something it works on. The science behind it is still unknown. The good thing about ganaxolone is it has very little side effects. So if one of the phases does well it is a gold mine! I traded on the momentum and will get back in a little cheaper and a lot less shares so there is no stress lol.

I like Epidiolex seems to be gaining momentum since it's FDA approval last year. It targets the same symptoms of ganaxolone with very little side effects also.

Good luck to you!
👍️0
UFO UFO 5 years ago
All I've seen them have an issue with is one trial. Now they have a treasure chest full of money and some aggressive money manager backing. IMHO, this would be the WORST time to bail out on the company. Did you read the corporate outlook that was released today? They have about 4 trials in progress and the ability to fund them all. You think ganaxolone is going to fail on all of them? I like the odds here. At the least I think we'll see a rally into the Phase 3 results that we'll see later this year. Go Marinus!

UFO
👍️0
Cosa Cosa 5 years ago
The more I research this stock the more I do not like. Ganaxolone doesnt look like it is doing well in clinical trials.
👍️0
ClayTrader ClayTrader 5 years ago
* * $MRNS Video Chart 12-24-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
Cosa Cosa 5 years ago
Could see that big move up sometime next month

https://www.nasdaq.com/articles/implied-volatility-surging-for-marinus-pharmaceuticals-mrns-stock-options-2019-12-23
👍️0
UFO UFO 5 years ago
Agreed. I've never seen a stock rally like this as a "major" financing is going on! Somebody knows something...just saying...

UFO
👍️0
Cosa Cosa 5 years ago
Possible 10 bagger with a short squeeze.
👍️0
UFO UFO 5 years ago
Go Marinus!

UFO
👍️0
ClayTrader ClayTrader 5 years ago
* * $MRNS Video Chart 12-20-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
UFO UFO 5 years ago
If they get GREAT results from their phase 3, this is a $40 - $50 stock!

UFO
👍️0
Cosa Cosa 5 years ago
If they pass a phase 3 this is going to $10 - $16
👍️0
Cosa Cosa 5 years ago
I'm late to the party. Just got in, more room to grow
👍️0
UFO UFO 5 years ago
Gap higher! Where are all you Marinus holders? This baby is on the move!

UFO
👍️0

Your Recent History

NASDAQ
MRNS
Marinus Pharmaceuticals
NYSE
WWW
Wolverine World Wide
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved